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However, caution should be taken
with respect to the chronic use of
metformin. MITF has been suggested to
be a key transcription factor for the
survival and proliferation of melano-
cytes. MITF was shown to upregulate
the expression of a major antiapoptotic
protein Bcl2, thus promoting the survival
of melanocytes (McGill et al., 2002). In
addition, MITF can induce or suppress
the melanocyte growth, depending on
the physiological conditions, by
modulating the expression of the cell
cycle–associated proteins such as kinase
Cdk2 and p21, a protein that inhibits
Cdk2 activation. Because MITF coop-
erates with other transcription factors to
induce its effects, it is to be expected that
these transcription factors would influ-
ence MITF activity, resulting in either
stimulation or inhibition of melanocyte
proliferation (reviewed in Park and Yaar,
2012). Therefore, prolonged exposure of
melanocytes to metformin may alter the
proliferation and/or survival of melano-
cytes. A more ideal drug to inhibit
pigmentation might target tyrosinase, an
enzyme, or its pathways that function
primarily to regulate pigmentation.
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Adult skin stem cells do not protect their genome by asymmetric chromosome
segregation; thus, they are prone to accumulating oncogenic mutations.
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It is widely accepted that genetic and
epigenetic aberrations have a strong
impact in determining the tumor phe-
notype. However, it is also accepted
that the cell of origin of a cancer affects
the tumor phenotype in a similar man-
ner. The cells of origin acquire the first
genetic or epigenetic hit or hits that
culminate in the initiation of cancer,
but they still retain some of their char-
acteristics, such as migratory capacity
(Gupta et al., 2005). For most types of
solid cancers, the cell of origin is still
unknown.
Identifying cells of origin of solid
cancers remains a challenging task in
cancer biology (Visvader, 2011). This
concept, however, is less applicable
to skin cancer. Indeed, skin is one of
the organs most suitable for examining
this question experimentally: (i) skin is
highly accessible; (ii) skin stem- and
transit-amplifying cell compartments
are well defined; and (iii) mouse
models of melanocytic and epithelial
skin cancers that recapitulate many of
the features of human cancers have now
been established. Nevertheless, there is
still room for new—and sometimes
unexpected—discovery.
Basal cell carcinoma (BCC) is the
most common type of skin cancer; as a
matter of fact, it is the most common
cancer in humans. The nomenclature
for BCC is explained by the histomor-
phological resemblance of cancer cells
to basal cells of the epidermis. Nearly
all BCCs exhibit constitutive activation
of the Hedgehog (Hh) signaling pathway
(Hahn et al., 1996). This pathway was
first identified in Drosophila melano-
gaster, but it is highly conserved,
from insects to vertebrates. Sonic
hedgehog (SHH) is the best-studied
ligand of the vertebrate pathway: In
response to binding of SHH to its
receptor patched-1 (Ptch1), Ptch1 stops
inhibiting smoothened (Smo), which
subsequently results in activation of the
GLI transcription factors. Loss of hetero-
zygosity of Ptch1 or activating mutations
in Smo can be detected in most forms
of BCC.
The observation that Hh signaling
represents the oncogenic driver aberra-
tion in BCC allowed the use of lineage
fate experiments to identify the cells
of origin of BCC. Only cancers with
known oncogenic driver genes allow
taking advantage of cell-specific Cre
expression to activate the respective
signaling pathway in the cell of
interest, and thus the possibility of
induced tumorigenesis. For BCC,
aberrant Hh signaling was clearly con-
firmed in mouse models. However,
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employing different mouse models
with an activated Hh signaling pathway,
i.e., Ptch1þ / or Smo-mutant mice,
adverted stem cells of the follicular
bulge or long-term resident progenitor
cells of the interfollicular epidermis,
respectively, as the cell of origin of
BCC (Donovan, 2009; Youssef et al.,
2010; Grachtchouk et al., 2011).
As more and more cell-specific Cre
alleles become available, lineage fate
experiments to map for cells of origin of
specific cancers are becoming more
common (Heffner et al., 2012). Indeed,
in this issue of the Journal, Uhmann
et al. (2014) described BCC develo-
pment in Ptchflox/floxCD4Creþ / mice,
in which Ptch1 was ablated in CD4Cre-
expressing cells. The T cell–specific
Ptch1 ablation did not interfere with
T-cell development, nor did it compro-
mise the function of T cells, but it
did render Ptchflox/floxCD4Creþ / mice
susceptible to chemically induced
BCC formation in the two-stage chemi-
cal carcinogenesis DMBA/TPA model.
By means of bone marrow transplanta-
tion and lineage tracing experiments,
as well as flow cytometry, the
authors demonstrated that the resulting
BCCs are derived from a newly discov-
ered rare CD4þ stem cell–like popula-
tion in the murine skin. These cells are
characterized by a distinct phenotype,
i.e., CD4þCD34intermediate Sca1þ
CD49fhigh, which has not been
described before.
Adult skin stem cells have a crucial
role in maintaining skin homeostasis. To
this end, different resident skin stem cell
pools contribute to the maintenance and
repair of the various epidermal tissues of
the skin (Blanpain and Fuchs, 2009).
Because adult skin stem cells do not
protect their genomes by asymmetric
chromosome segregation, they are
prone to accumulating oncogenic muta-
tions that potentially induce cancer
formation. It will be interesting to see
whether the newly described
CD4þCD34intermediate Sca1þCD49fhigh
are more predominant in the follicular
bulge or in the interfollicular epidermis,
thus providing new information about
the cell of origin of BCC.
Identifying the cells of
origin of solid cancers is
a challenging task in
cancer biology; this
concept, however, is
less applicable for
skin cancer.
An even more active discussion has
taken place recently concerning the cell
of origin of a rare skin cancer: cuta-
neous neuroendocrine carcinoma (Mer-
kel cell carcinoma (MCC)). While the
genesis of MCC has been strongly linked
to the Merkel cell polyomavirus
(MCPyV), the cell of origin is still a
matter of debate (Arora et al., 2012;
Tilling and Moll, 2012). Initially, based
on the phenotypic similarities of its
tumor cells with the neuroendocrine
cells of the skin, i.e., Merkel cells,
these cells were believed to be the
origin of MCC. This phenotypic
association was responsible for the
nomenclature of this tumor. However,
because Merkel cells are in a postmi-
totic resting state, it is not likely that
MCC develops from differentiated
Merkel cells. To this end, epithelial
stem cells in adult mammalian skin are
known to maintain interfollicular epi-
dermis, hair follicles, and sebaceous
glands by providing cells for the
respective lineages during homeostasis.
By means of lineage tracking experi-
ments Merkel cells were identified as a
fourth lineage derived from the prolife-
rative layer of murine skin epithelium
(Van Keymeulen et al., 2009; Woo et al.,
2010). Thus, skin stem cells are more
likely to be the cells of origin for MCC.
However, the most recent evidence
suggests hematopoietic cells, more
precisely pro/pre- or pre-B cells, as
possible cells of origin of MCC (zur
Hausen et al., 2013). Notably, MCPyV
infection and transformation of pro-/pre-
B cells are likely to induce the expre-
ssion of simple cytokeratins, as has been
shown for SV40 in other nonepithelial
cells (Knapp and Franke, 1989).
Identification of the cells of origin in
cancer may allow the recognition of
individuals with increased susceptibility
for the specific cancer entities, allowing
earlier detection of cancer, better pre-
diction of cancer characteristics, as well
as behavior, and, ultimately, preventive
therapies for individuals at high risk for
skin cancer.
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Clinical Implications
The identification of the cells of origin in a specific cancer may allow:
 Prediction of cancer characteristics and behavior.
 Recognition of individuals with increased susceptibility for the respec-
tive cancers.
 Earlier detection.
 Preventive therapies for individuals at high risk.
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Epidermal, Sebaceous, and
Melanocytic Nevoid Proliferations Are
Spectrums of Mosaic RASopathies
Su Luo1 and Hensin Tsao1,2
Growing evidence demonstrates that various nevoid proliferations such as
keratinocytic epidermal nevi and nevus sebaceous result from somatic mosaicism.
Many of the mutations identified have been within the RAF/RAS/MAPK pathway,
hence supporting the previously introduced term "mosaic RASopathy" for these
nevi. In this issue, Kinsler et al. were among the first to characterize certain
pigmented melanocytic nevi that may also fit this paradigm. To better frame these
findings, we provide a summary of the analogous genotypic profiles for epidermal
and melanocytic nevi from recent studies.
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Mosaicism is the presence of two dis-
tinct populations of cells that express
differing phenotypes in one organism,
resulting from a postzygotic mutation.
Cutaneous mosaicism, being readily
apparent, represents a unique opportu-
nity to study such genetic events. Var-
ious patterns found on the skin, such as
the lines of Blaschko and the checker-
board and phylloid (leaf-life) patterns,
are well-known manifestations of
mosaicism (Happle, 1993).
Nevoid proliferations make obvious
mosaic presentations when they are
extensive. Examples include systema-
tized keratinocytic epidermal nevi
as well as the Schimmelpenning
syndrome, in which a widespread
nevus sebaceous (NS) is associated with
extracutaneous defects. The molecular
basis for these phenotypic expre-
ssions are continually being elucidated
(Bourdeaut et al., 2010; Groesser et al.,
2012). In addition, inferences from
these observations have led to con-
comitant genetic analyses of the
common keratinocytic epidermal nevus
(KEN) and NS. These analyses revealed
the equivalent role of mosaicism in
these isolated nevi, which also often
follow the lines of Blaschko. Strikingly,
several common hotspot mutations in
the RAS oncogenes are recurrent in such
nevi.
Table 1 provides a summary of studies
genotyping the available mosaic pheno-
types divided into nevoid types. Hafner
et al. (2011) first presented a case of a
systematized KEN with multiple urothe-
lial carcinomas stemming from a mosaic
HRAS p.G12S mutation. They subse-
quently showed that an adjacent HRAS
mutation, p.G13R, was present as the
somatic mutation in nearly a third of
KEN, identifying it as a new hotspot for
mutation (Hafner et al., 2012). These
oncogenic mosaics were distinct from
previously described ones involving
FGFR3 and PIK3CA, which are seen in
less than half of KEN. Rare KRAS
p.G12D mutations were also found by
Hafner’s group, previously reported in a
clinical case of epidermal nevus with
rhabdomyosarcoma (Bourdeaut et al.,
2010). Various functional assays have
proven that these hotspot RAS mutations
cause constitutive activation of the RAS/
RAF/MAPK pathway (Groesser et al.,
2012; Sun et al., 2013).
Taken together, these studies support
KEN as a ‘‘mosaic RASopathy’’, a term
first introduced by Hafner. This term
expanded on the concept of RASopa-
thies, a heterogeneous collection of
syndromes resulting from germline
mutations in oncogenes involved in
the RAS/RAF/MAPK pathway, including
Costello, Noonan, Cardio–facio–cuta-
neous, and Neurofibromatosis-1 syn-
dromes. In the case of KEN, somatic
mutations in this pathway lead to a
mosaic presentation of a phenotypi-
cally distinct entity with essentially
no clinical overlap with the germline
conditions (Hafner et al., 2012).
Other authors have demonstrated in
parallel that NS is also a mosaic RASo-
pathy. Groesser et al. (2013) reported
that up to 95% of sampled NS harbored
the HRAS mutations, most frequently
again with p.G13R. They also found
KRAS p.G12D mutations on rare
occasions, which have been seen in
KEN as well. Using whole-exome
sequencing, Levinsohn et al. (2013)
examined five index samples of NS and
identified the HRAS p.G13R hotspot
mutation in three specimens, whereas
the two remaining featured two KRAS
mutations, p.G12D and p.G12V. Further
analysis of archival specimens supported
the predominance of HRAS p.G13R in
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